ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025

Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis.

Camille Rigollet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.